Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism

Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume. This 52-wee...

Full description

Saved in:
Bibliographic Details
Published inClinical journal of the American Society of Nephrology Vol. 5; no. 12; pp. 2305 - 2314
Main Authors Komaba, Hirotaka, Nakanishi, Shohei, Fujimori, Akira, Tanaka, Motoko, Shin, Jeongsoo, Shibuya, Koji, Nishioka, Masato, Hasegawa, Hirohito, Kurosawa, Takeshi, Fukagawa, Masafumi
Format Journal Article
LanguageEnglish
Published United States American Society of Nephrology 01.12.2010
SeriesOriginal Articles
Subjects
Online AccessGet full text
ISSN1555-9041
1555-905X
1555-905X
DOI10.2215/CJN.02110310

Cover

Abstract Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume. This 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH <180 pg/ml. Ultrasonography was performed to measure the parathyroid gland size at baseline, week 26, and week 52. Findings were also compared with those of historical controls. Of the 81 subjects enrolled, 56 had parathyroid glands smaller than 500 mm(3) (group S) and 25 had at least one enlarged gland larger than 500 mm(3) (group L). Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L. A slightly greater proportion of patients in group S versus group L achieved an intact PTH <180 pg/ml (46 versus 32%) and a >30% reduction from baseline (88 versus 78%), but this was not statistically significant. Cinacalcet therapy also resulted in a significant reduction in parathyroid gland volume regardless of pretreatment size, which was in sharp contrast to historical controls (n = 87) where parathyroid gland volume progressively increased with traditional therapy alone. Cinacalcet effectively decreases serum PTH levels and concomitantly reduces parathyroid gland volume, even in patients with marked parathyroid hyperplasia.
AbstractList Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume. This 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH <180 pg/ml. Ultrasonography was performed to measure the parathyroid gland size at baseline, week 26, and week 52. Findings were also compared with those of historical controls. Of the 81 subjects enrolled, 56 had parathyroid glands smaller than 500 mm(3) (group S) and 25 had at least one enlarged gland larger than 500 mm(3) (group L). Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L. A slightly greater proportion of patients in group S versus group L achieved an intact PTH <180 pg/ml (46 versus 32%) and a >30% reduction from baseline (88 versus 78%), but this was not statistically significant. Cinacalcet therapy also resulted in a significant reduction in parathyroid gland volume regardless of pretreatment size, which was in sharp contrast to historical controls (n = 87) where parathyroid gland volume progressively increased with traditional therapy alone. Cinacalcet effectively decreases serum PTH levels and concomitantly reduces parathyroid gland volume, even in patients with marked parathyroid hyperplasia.
Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume.BACKGROUND AND OBJECTIVESCinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume.This 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH <180 pg/ml. Ultrasonography was performed to measure the parathyroid gland size at baseline, week 26, and week 52. Findings were also compared with those of historical controls.DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTSThis 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH <180 pg/ml. Ultrasonography was performed to measure the parathyroid gland size at baseline, week 26, and week 52. Findings were also compared with those of historical controls.Of the 81 subjects enrolled, 56 had parathyroid glands smaller than 500 mm(3) (group S) and 25 had at least one enlarged gland larger than 500 mm(3) (group L). Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L. A slightly greater proportion of patients in group S versus group L achieved an intact PTH <180 pg/ml (46 versus 32%) and a >30% reduction from baseline (88 versus 78%), but this was not statistically significant. Cinacalcet therapy also resulted in a significant reduction in parathyroid gland volume regardless of pretreatment size, which was in sharp contrast to historical controls (n = 87) where parathyroid gland volume progressively increased with traditional therapy alone.RESULTSOf the 81 subjects enrolled, 56 had parathyroid glands smaller than 500 mm(3) (group S) and 25 had at least one enlarged gland larger than 500 mm(3) (group L). Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L. A slightly greater proportion of patients in group S versus group L achieved an intact PTH <180 pg/ml (46 versus 32%) and a >30% reduction from baseline (88 versus 78%), but this was not statistically significant. Cinacalcet therapy also resulted in a significant reduction in parathyroid gland volume regardless of pretreatment size, which was in sharp contrast to historical controls (n = 87) where parathyroid gland volume progressively increased with traditional therapy alone.Cinacalcet effectively decreases serum PTH levels and concomitantly reduces parathyroid gland volume, even in patients with marked parathyroid hyperplasia.CONCLUSIONSCinacalcet effectively decreases serum PTH levels and concomitantly reduces parathyroid gland volume, even in patients with marked parathyroid hyperplasia.
Background and objectives: Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether parathyroid gland size predicts response to therapy and whether cinacalcet is capable of inducing a reduction in parathyroid volume. Design, setting, participants, & measurements: This 52-week, multicenter, open-label study enrolled hemodialysis patients with moderate to severe secondary hyperparathyroidism (intact PTH >300 pg/ml). Doses of cinacalcet were adjusted between 25 and 100 mg to achieve intact PTH <180 pg/ml. Ultrasonography was performed to measure the parathyroid gland size at baseline, week 26, and week 52. Findings were also compared with those of historical controls. Results: Of the 81 subjects enrolled, 56 had parathyroid glands smaller than 500 mm3 (group S) and 25 had at least one enlarged gland larger than 500 mm3 (group L). Treatment with cinacalcet effectively decreased intact PTH by 55% from baseline in group S and by 58% in group L. A slightly greater proportion of patients in group S versus group L achieved an intact PTH <180 pg/ml (46 versus 32%) and a >30% reduction from baseline (88 versus 78%), but this was not statistically significant. Cinacalcet therapy also resulted in a significant reduction in parathyroid gland volume regardless of pretreatment size, which was in sharp contrast to historical controls (n = 87) where parathyroid gland volume progressively increased with traditional therapy alone. Conclusions: Cinacalcet effectively decreases serum PTH levels and concomitantly reduces parathyroid gland volume, even in patients with marked parathyroid hyperplasia.
Author Jeongsoo Shin
Takeshi Kurosawa
Masato Nishioka
Shohei Nakanishi
Hirohito Hasegawa
Hirotaka Komaba
Akira Fujimori
Koji Shibuya
Motoko Tanaka
Masafumi Fukagawa
Author_xml – sequence: 1
  givenname: Hirotaka
  surname: Komaba
  fullname: Komaba, Hirotaka
– sequence: 2
  givenname: Shohei
  surname: Nakanishi
  fullname: Nakanishi, Shohei
– sequence: 3
  givenname: Akira
  surname: Fujimori
  fullname: Fujimori, Akira
– sequence: 4
  givenname: Motoko
  surname: Tanaka
  fullname: Tanaka, Motoko
– sequence: 5
  givenname: Jeongsoo
  surname: Shin
  fullname: Shin, Jeongsoo
– sequence: 6
  givenname: Koji
  surname: Shibuya
  fullname: Shibuya, Koji
– sequence: 7
  givenname: Masato
  surname: Nishioka
  fullname: Nishioka, Masato
– sequence: 8
  givenname: Hirohito
  surname: Hasegawa
  fullname: Hasegawa, Hirohito
– sequence: 9
  givenname: Takeshi
  surname: Kurosawa
  fullname: Kurosawa, Takeshi
– sequence: 10
  givenname: Masafumi
  surname: Fukagawa
  fullname: Fukagawa, Masafumi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20798251$$D View this record in MEDLINE/PubMed
BookMark eNpdUk1vEzEUXKEi-gE3zsg3OLDF9tq72QsSikoDqqCigLhZL963iatde7G9jcLP4ZfiKGlacrEte97Mm3k-zY6ss5hlLxk955zJd9PPX84pZ4wWjD7JTpiUMq-p_HW0Pwt2nJ2GcEupEAWXz7JjTqt6wiU7yf5OjQUNncZILtoWdTR32K3JN2xGjYFcg4e4XHtnGjJzvk_a5Aa1x2icJWAbctlt1p-uG3tMZQvwTYchENeS6wTzCLFHG3e4G_MHibGJN5p0G8jKxOWG0dkG_JrM1gP64UHUhP559rSFLuCL3X6W_fh48X06y6--Xn6afrjKtWBlzOt5NWespCW0VGuhmwZ0WwOTTKOYSIkNcAEVF1VBeVvVNUOkAopSaC2LUhdnWb7lHe0A6xV0nRq86VNXilG1yVrpW6vus07491v8MM57bHSy4-GhxoFR_79Ys1QLd6d4XQtaF4ng9Y7Au98jhqh6EzR2KSh0Y1ATVlZ1UYmN1KvHUnuN-zkmAN8CtHcheGyVNhE2M0rKptsbSJ_lsYG3B0WHfg_gb7bwpVksV8ajCn0KKbXEUzAQrFSMK15QWfwDIU_RFQ
CitedBy_id crossref_primary_10_3389_fendo_2024_1495818
crossref_primary_10_1016_j_jss_2022_12_030
crossref_primary_10_1007_s11560_012_0652_9
crossref_primary_10_1111_ctr_13988
crossref_primary_10_1088_1361_6528_aaef46
crossref_primary_10_1111_cen_12326
crossref_primary_10_1021_acs_analchem_3c03846
crossref_primary_10_3389_fmed_2022_1007887
crossref_primary_10_1093_ndt_gfr589
crossref_primary_10_4103_ijem_IJEM_292_19
crossref_primary_10_3389_fmed_2021_704970
crossref_primary_10_1111_1744_9987_13553
crossref_primary_10_1016_j_ekir_2023_08_034
crossref_primary_10_2217_fca_11_82
crossref_primary_10_1152_physrev_00015_2012
crossref_primary_10_1080_17446651_2020_1780911
crossref_primary_10_4009_jsdt_46_519
crossref_primary_10_1111_j_1525_139X_2011_00853_x
crossref_primary_10_1016_j_nefroe_2015_10_004
crossref_primary_10_1007_s10157_011_0502_5
crossref_primary_10_3389_fpubh_2021_712027
crossref_primary_10_1007_s00726_022_03126_8
crossref_primary_10_1371_journal_pone_0186093
crossref_primary_10_1016_j_ekir_2021_08_020
crossref_primary_10_1186_s41100_017_0131_x
crossref_primary_10_4009_jsdt_51_681
crossref_primary_10_1371_journal_pone_0316675
crossref_primary_10_1096_fj_15_274191
crossref_primary_10_1080_0886022X_2018_1562356
crossref_primary_10_1111_1744_9987_12292
crossref_primary_10_1186_s12882_021_02361_7
crossref_primary_10_1210_clinem_dgac142
crossref_primary_10_1007_s00423_016_1546_5
crossref_primary_10_1093_ndt_gfr645
crossref_primary_10_1007_s13730_024_00924_9
crossref_primary_10_1111_1744_9987_12329
crossref_primary_10_1111_1744_9987_12604
crossref_primary_10_3390_ijms20112800
crossref_primary_10_1111_j_1525_139X_2011_00935_x
crossref_primary_10_3389_ti_2024_12704
crossref_primary_10_3389_fendo_2023_1169793
crossref_primary_10_1186_1752_1947_6_417
crossref_primary_10_1016_j_eprac_2021_08_003
crossref_primary_10_1016_j_beem_2013_02_008
crossref_primary_10_1186_s41100_024_00529_z
crossref_primary_10_1053_j_jrn_2013_09_001
crossref_primary_10_1371_journal_pone_0232428
crossref_primary_10_1016_j_nefroe_2015_09_002
crossref_primary_10_1016_j_ijsu_2014_05_019
crossref_primary_10_1093_ndt_gfw408
crossref_primary_10_1080_14656566_2024_2441328
crossref_primary_10_3349_ymj_2013_54_2_453
crossref_primary_10_1093_ndt_gfs568
crossref_primary_10_1111_cen_12333
crossref_primary_10_1111_1744_9987_12058
crossref_primary_10_31450_ukrjnd_1_73__2022_02
crossref_primary_10_1517_14656566_2013_783017
crossref_primary_10_4009_jsdt_56_215
crossref_primary_10_1007_s10157_016_1369_2
crossref_primary_10_1111_nep_12536
crossref_primary_10_1093_ndt_gfr384
crossref_primary_10_1186_s12882_015_0077_6
crossref_primary_10_3390_ijms21124332
crossref_primary_10_1016_j_nefro_2015_06_018
crossref_primary_10_1186_1471_2482_13_S2_S4
crossref_primary_10_1016_j_nefro_2015_06_013
crossref_primary_10_1080_14656566_2017_1303482
crossref_primary_10_1093_ckj_sfx125
crossref_primary_10_1254_fpj_150_98
crossref_primary_10_1093_ckj_sfae391
crossref_primary_10_2215_CJN_01760215
crossref_primary_10_1093_ckj_sfz021
crossref_primary_10_1007_BF03344777
crossref_primary_10_1016_j_transproceed_2019_01_141
crossref_primary_10_5301_GTND_2013_11690
crossref_primary_10_4009_jsdt_54_21
crossref_primary_10_1007_s10354_015_0379_0
crossref_primary_10_1111_sdi_12521
crossref_primary_10_1210_jc_2013_4050
crossref_primary_10_4061_2011_906832
crossref_primary_10_1093_ckj_sfy062
crossref_primary_10_4009_jsdt_45_301
crossref_primary_10_1007_s40620_019_00677_0
crossref_primary_10_1038_nrneph_2012_116
crossref_primary_10_1007_s00423_015_1344_5
crossref_primary_10_2169_naika_101_1325
crossref_primary_10_1111_sdi_12413
crossref_primary_10_1038_srep19612
crossref_primary_10_1053_j_ajkd_2011_12_034
crossref_primary_10_7759_cureus_16388
crossref_primary_10_1016_j_nephro_2010_12_010
crossref_primary_10_1038_kisup_2013_94
crossref_primary_10_2215_CJN_06040710
crossref_primary_10_1093_ndt_gfw205
crossref_primary_10_1111_j_1744_9987_2011_00928_x
crossref_primary_10_34172_PS_2023_30
crossref_primary_10_1007_s12020_012_9711_2
crossref_primary_10_1530_EJE_12_0947
crossref_primary_10_1038_nrneph_2013_130
crossref_primary_10_4158_EP14483_OR
crossref_primary_10_3109_0886022X_2013_832319
crossref_primary_10_1007_s11547_012_0882_x
crossref_primary_10_1111_1744_9987_12772
crossref_primary_10_1007_s00774_020_01190_2
Cites_doi 10.1056/NEJM199008093230617
10.2215/CJN.03591006
10.1681/ASN.V115903
10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z
10.1038/ki.1997.41
10.1111/j.1523-1755.2002.kid585.x
10.1681/ASN.2004060512
10.1111/j.1744-9987.2008.00631.x
10.1159/000188261
10.1056/NEJMoa031633
10.2215/CJN.01040308
10.1007/s00774-006-0687-y
10.1038/sj.ki.5002287
10.1097/01.ASN.0000050224.03126.AD
10.1093/ndt/gfg451
10.1093/ndt/gfn654
10.1111/j.1523-1755.2005.00596.x
10.1172/JCI116720
10.1093/ndt/gfn717
10.1093/ndt/gfn026
10.1681/ASN.V1341017
10.1093/ndt/gfm177
10.1093/ndt/gfm534
10.1038/ki.1994.223
10.1152/ajprenal.00262.2006
10.1038/sj.ki.5001594
10.1111/j.1744-9987.2006.00364.x
10.1136/bmj.4.5893.643
10.1097/01.ASN.0000141016.20133.33
10.2215/CJN.04150907
10.1681/ASN.V1161141
10.1172/JCI119851
10.1111/j.1523-1755.2005.67103.x
10.1111/j.1523-1755.2000.00370.x
10.7326/0003-4819-147-12-200712180-00004
ContentType Journal Article
Copyright Copyright © 2010 by the American Society of Nephrology 2010
Copyright_xml – notice: Copyright © 2010 by the American Society of Nephrology 2010
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.2215/CJN.02110310
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1555-905X
EndPage 2314
ExternalDocumentID oai:pubmedcentral.nih.gov:2994093
PMC2994093
20798251
10_2215_CJN_02110310
cjasn5_12_2305
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GroupedDBID -
0R
29B
2WC
53G
5GY
5VS
AAWTL
ADACO
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CS3
DIK
DU5
EBS
EJD
F5P
FH7
GX1
H13
HYE
HZ
KQ8
O9-
OK1
P2P
RHF
RHI
RPM
TNP
WOQ
ZA5
---
0R~
6PF
AAOCO
AAQQT
AAUIN
AAYXX
ABBLC
ABJNI
ABXYN
ACLDA
ACZKN
ADSXY
AFEXH
AFNMH
AHOMT
AHQVU
BTFSW
BYPQX
CITATION
ERAAH
HZ~
OVD
RIG
TEORI
TR2
W8F
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c416t-9b7b11606af0cc4cddacf9a151ce4855eda24a7247302f7991ee04a364cc536c3
IEDL.DBID UNPAY
ISSN 1555-9041
1555-905X
IngestDate Wed Aug 20 00:11:09 EDT 2025
Tue Sep 30 16:37:53 EDT 2025
Fri Jul 11 04:18:44 EDT 2025
Mon Jul 21 05:58:49 EDT 2025
Thu Apr 24 22:57:42 EDT 2025
Wed Oct 01 02:39:28 EDT 2025
Tue Jan 05 20:16:26 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c416t-9b7b11606af0cc4cddacf9a151ce4855eda24a7247302f7991ee04a364cc536c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/2994093
PMID 20798251
PQID 816793740
PQPubID 23479
PageCount 10
ParticipantIDs unpaywall_primary_10_2215_cjn_02110310
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2994093
proquest_miscellaneous_816793740
pubmed_primary_20798251
crossref_citationtrail_10_2215_CJN_02110310
crossref_primary_10_2215_CJN_02110310
highwire_smallpub2_cjasn5_12_2305
ProviderPackageCode RHF
RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20101201
2010-12-00
2010-Dec
PublicationDateYYYYMMDD 2010-12-01
PublicationDate_xml – month: 12
  year: 2010
  text: 20101201
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationSeriesTitle Original Articles
PublicationTitle Clinical journal of the American Society of Nephrology
PublicationTitleAlternate Clin J Am Soc Nephrol
PublicationYear 2010
Publisher American Society of Nephrology
Publisher_xml – name: American Society of Nephrology
References Gogusev (R8-24-20230601) 1997; 51
Payne (R31-24-20230601) 1973; 4
Rodriguez (R33-24-20230601) 2007; 292
Fukagawa (R14-24-20230601) 1990; 323
Yano (R9-24-20230601) 2000; 58
Meola (R26-24-20230601) 2009; 24
Block (R18-24-20230601) 2004; 350
Drueke (R28-24-20230601) 2007; 22
Messa (R24-24-20230601) 2008; 3
Komaba (R21-24-20230601) 2008; 12
Fishbane (R23-24-20230601) 2008; 3
Quarles (R17-24-20230601) 2003; 14
Chin (R27-24-20230601) 2000; 11
Fukagawa (R11-24-20230601) 1994; 68
Goodman (R2-24-20230601) 2008; 74
Tominaga (R13-24-20230601) 2006; 10
Lindberg (R19-24-20230601) 2005; 16
Cunningham (R38-24-20230601) 2005; 68
Fukagawa (R4-24-20230601) 2006; 70
Tokumoto (R10-24-20230601) 2002; 62
Fukuda (R6-24-20230601) 1993; 92
Tanaka (R25-24-20230601) 2008; 1
Colloton (R36-24-20230601) 2005; 67
Tominaga (R3-24-20230601) 1997; 13
Okuno (R12-24-20230601) 2003; 18
Komaba (R29-24-20230601) 2009; 24
Lomonte (R37-24-20230601) 2008; 3
Mizobuchi (R34-24-20230601) 2004; 15
Kawata (R32-24-20230601) 2006; 24
Block (R22-24-20230601) 2008; 23
Fukagawa (R20-24-20230601) 2008; 23
Drueke (R1-24-20230601) 2000; 11
Quarles (R15-24-20230601) 1994; 45
Palmer (R5-24-20230601) 2007; 147
Wada (R35-24-20230601) 1997; 100
Kifor (R7-24-20230601) 1996; 81
Goodman (R16-24-20230601) 2002; 13
25983974 - NDT Plus. 2008 Aug;1(Suppl 3):iii49-iii53
20091692 - Head Neck. 2010 Sep;32(9):1226-35
19181759 - Nephrol Dial Transplant. 2009 Mar;24(3):982-9
19644521 - Kidney Int Suppl. 2009 Aug;(113):S1-130
19140852 - Ther Apher Dial. 2008 Dec;12(6):514-25
7830860 - Nephron. 1994;68(2):221-8
8995751 - Kidney Int. 1997 Jan;51(1):328-36
17449493 - Nephrol Dial Transplant. 2007 Jul;22(7):1828-39
18087055 - Ann Intern Med. 2007 Dec 18;147(12):840-53
11044218 - Kidney Int. 2000 Nov;58(5):1980-6
17568787 - Kidney Int. 2008 Aug;74(3):276-88
15071126 - N Engl J Med. 2004 Apr 8;350(15):1516-25
16810308 - Kidney Int Suppl. 2006 Jul;(102):S3-7
8397225 - J Clin Invest. 1993 Sep;92(3):1436-43
16816924 - J Bone Miner Metab. 2006;24(4):300-6
17200160 - Am J Physiol Renal Physiol. 2007 May;292(5):F1390-5
17717030 - Nephrol Dial Transplant. 2008 Jan;23(1):328-35
4758544 - Br Med J. 1973 Dec 15;4(5893):643-6
2370898 - N Engl J Med. 1990 Aug 9;323(6):421-2
9088063 - Semin Surg Oncol. 1997 Mar-Apr;13(2):78-86
15673294 - Kidney Int. 2005 Feb;67(2):467-76
18945995 - Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25
19032527 - Ther Apher Dial. 2008 Oct;12 Suppl 1:S44-9
12234290 - Kidney Int. 2002 Oct;62(4):1196-207
19103739 - Nephrol Dial Transplant. 2009 Mar;24(3):707-9
10770968 - J Am Soc Nephrol. 2000 May;11(5):903-11
16164656 - Kidney Int. 2005 Oct;68(4):1793-800
11912261 - J Am Soc Nephrol. 2002 Apr;13(4):1017-24
7933819 - Kidney Int. 1994 Jun;45(6):1710-21
18322048 - Clin J Am Soc Nephrol. 2008 May;3(3):794-9
15466262 - J Am Soc Nephrol. 2004 Oct;15(10):2579-87
14605286 - Nephrol Dial Transplant. 2003 Dec;18(12):2613-21
15689407 - J Am Soc Nephrol. 2005 Mar;16(3):800-7
9399943 - J Clin Invest. 1997 Dec 15;100(12):2977-83
10820180 - J Am Soc Nephrol. 2000 Jun;11(6):1141-52
18310602 - Nephrol Dial Transplant. 2008 Jul;23(7):2311-8
8636374 - J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606
18178780 - Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45
16684224 - Ther Apher Dial. 2006 Apr;10(2):198-204
12595492 - J Am Soc Nephrol. 2003 Mar;14(3):575-83
References_xml – volume: 323
  start-page: 421
  year: 1990
  ident: R14-24-20230601
  article-title: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199008093230617
– volume: 3
  start-page: 36
  year: 2008
  ident: R24-24-20230601
  article-title: The OPTIMA study: Assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.03591006
– volume: 11
  start-page: 903
  year: 2000
  ident: R27-24-20230601
  article-title: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V115903
– volume: 1
  start-page: iii49
  year: 2008
  ident: R25-24-20230601
  article-title: Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism
  publication-title: NDT Plus
– volume: 13
  start-page: 78
  year: 1997
  ident: R3-24-20230601
  article-title: Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism
  publication-title: Semin Surg Oncol
  doi: 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z
– volume: 51
  start-page: 328
  year: 1997
  ident: R8-24-20230601
  article-title: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism
  publication-title: Kidney Int
  doi: 10.1038/ki.1997.41
– volume: 62
  start-page: 1196
  year: 2002
  ident: R10-24-20230601
  article-title: Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2002.kid585.x
– volume: 16
  start-page: 800
  year: 2005
  ident: R19-24-20230601
  article-title: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized double-blind, multicenter study
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2004060512
– volume: 12
  start-page: S44
  year: 2008
  ident: R21-24-20230601
  article-title: Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: A post-hoc analysis of the KRN1493 study
  publication-title: Ther Apher Dial
  doi: 10.1111/j.1744-9987.2008.00631.x
– volume: 68
  start-page: 221
  year: 1994
  ident: R11-24-20230601
  article-title: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patient
  publication-title: Nephron
  doi: 10.1159/000188261
– volume: 350
  start-page: 1516
  year: 2004
  ident: R18-24-20230601
  article-title: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa031633
– volume: 3
  start-page: 1718
  year: 2008
  ident: R23-24-20230601
  article-title: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: The ACHIEVE study results
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.01040308
– volume: 24
  start-page: 300
  year: 2006
  ident: R32-24-20230601
  article-title: Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels
  publication-title: J Bone Miner Metab
  doi: 10.1007/s00774-006-0687-y
– volume: 74
  start-page: 276
  year: 2008
  ident: R2-24-20230601
  article-title: Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5002287
– volume: 14
  start-page: 575
  year: 2003
  ident: R17-24-20230601
  article-title: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease
  publication-title: J Am Soc Nephrol
  doi: 10.1097/01.ASN.0000050224.03126.AD
– volume: 18
  start-page: 2613
  year: 2003
  ident: R12-24-20230601
  article-title: Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfg451
– volume: 24
  start-page: 982
  year: 2009
  ident: R26-24-20230601
  article-title: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfn654
– volume: 68
  start-page: 1793
  year: 2005
  ident: R38-24-20230601
  article-title: Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2005.00596.x
– volume: 92
  start-page: 1436
  year: 1993
  ident: R6-24-20230601
  article-title: Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
  publication-title: J Clin Invest
  doi: 10.1172/JCI116720
– volume: 24
  start-page: 707
  year: 2009
  ident: R29-24-20230601
  article-title: Regression of parathyroid hyperplasia by calcimimetics—fact or illusion?
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfn717
– volume: 23
  start-page: 2311
  year: 2008
  ident: R22-24-20230601
  article-title: Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfn026
– volume: 13
  start-page: 1017
  year: 2002
  ident: R16-24-20230601
  article-title: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V1341017
– volume: 22
  start-page: 1828
  year: 2007
  ident: R28-24-20230601
  article-title: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfm177
– volume: 23
  start-page: 328
  year: 2008
  ident: R20-24-20230601
  article-title: Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients
  publication-title: Nephrol Dial Transplant
  doi: 10.1093/ndt/gfm534
– volume: 45
  start-page: 1710
  year: 1994
  ident: R15-24-20230601
  article-title: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
  publication-title: Kidney Int
  doi: 10.1038/ki.1994.223
– volume: 292
  start-page: F1390
  year: 2007
  ident: R33-24-20230601
  article-title: The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands
  publication-title: Am J Physiol Renal Physiol
  doi: 10.1152/ajprenal.00262.2006
– volume: 70
  start-page: S3
  year: 2006
  ident: R4-24-20230601
  article-title: Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease
  publication-title: Kidney Int
  doi: 10.1038/sj.ki.5001594
– volume: 10
  start-page: 198
  year: 2006
  ident: R13-24-20230601
  article-title: Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism?
  publication-title: Ther Apher Dial
  doi: 10.1111/j.1744-9987.2006.00364.x
– volume: 4
  start-page: 643
  year: 1973
  ident: R31-24-20230601
  article-title: Interpretation of serum calcium levels in patients with abnormal serum proteins
  publication-title: BMJ
  doi: 10.1136/bmj.4.5893.643
– volume: 15
  start-page: 2579
  year: 2004
  ident: R34-24-20230601
  article-title: Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency
  publication-title: J Am Soc Nephrol
  doi: 10.1097/01.ASN.0000141016.20133.33
– volume: 3
  start-page: 794
  year: 2008
  ident: R37-24-20230601
  article-title: Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/CJN.04150907
– volume: 11
  start-page: 1141
  year: 2000
  ident: R1-24-20230601
  article-title: Cell biology of parathyroid gland hyperplasia in chronic renal failure
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.V1161141
– volume: 100
  start-page: 2977
  year: 1997
  ident: R35-24-20230601
  article-title: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor
  publication-title: J Clin Invest
  doi: 10.1172/JCI119851
– volume: 81
  start-page: 1598
  year: 1996
  ident: R7-24-20230601
  article-title: Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism
  publication-title: J Clin Endocrinol Metab
– volume: 67
  start-page: 467
  year: 2005
  ident: R36-24-20230601
  article-title: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2005.67103.x
– volume: 58
  start-page: 1980
  year: 2000
  ident: R9-24-20230601
  article-title: Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2000.00370.x
– volume: 147
  start-page: 840
  year: 2007
  ident: R5-24-20230601
  article-title: Meta-analysis: Vitamin D compounds in chronic kidney disease
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-147-12-200712180-00004
– reference: 7933819 - Kidney Int. 1994 Jun;45(6):1710-21
– reference: 9399943 - J Clin Invest. 1997 Dec 15;100(12):2977-83
– reference: 18322048 - Clin J Am Soc Nephrol. 2008 May;3(3):794-9
– reference: 19181759 - Nephrol Dial Transplant. 2009 Mar;24(3):982-9
– reference: 12234290 - Kidney Int. 2002 Oct;62(4):1196-207
– reference: 11912261 - J Am Soc Nephrol. 2002 Apr;13(4):1017-24
– reference: 20091692 - Head Neck. 2010 Sep;32(9):1226-35
– reference: 15689407 - J Am Soc Nephrol. 2005 Mar;16(3):800-7
– reference: 18087055 - Ann Intern Med. 2007 Dec 18;147(12):840-53
– reference: 15071126 - N Engl J Med. 2004 Apr 8;350(15):1516-25
– reference: 17449493 - Nephrol Dial Transplant. 2007 Jul;22(7):1828-39
– reference: 16684224 - Ther Apher Dial. 2006 Apr;10(2):198-204
– reference: 17200160 - Am J Physiol Renal Physiol. 2007 May;292(5):F1390-5
– reference: 19140852 - Ther Apher Dial. 2008 Dec;12(6):514-25
– reference: 15466262 - J Am Soc Nephrol. 2004 Oct;15(10):2579-87
– reference: 25983974 - NDT Plus. 2008 Aug;1(Suppl 3):iii49-iii53
– reference: 4758544 - Br Med J. 1973 Dec 15;4(5893):643-6
– reference: 18178780 - Clin J Am Soc Nephrol. 2008 Jan;3(1):36-45
– reference: 18310602 - Nephrol Dial Transplant. 2008 Jul;23(7):2311-8
– reference: 8397225 - J Clin Invest. 1993 Sep;92(3):1436-43
– reference: 8995751 - Kidney Int. 1997 Jan;51(1):328-36
– reference: 10820180 - J Am Soc Nephrol. 2000 Jun;11(6):1141-52
– reference: 2370898 - N Engl J Med. 1990 Aug 9;323(6):421-2
– reference: 16164656 - Kidney Int. 2005 Oct;68(4):1793-800
– reference: 19032527 - Ther Apher Dial. 2008 Oct;12 Suppl 1:S44-9
– reference: 17717030 - Nephrol Dial Transplant. 2008 Jan;23(1):328-35
– reference: 19644521 - Kidney Int Suppl. 2009 Aug;(113):S1-130
– reference: 16816924 - J Bone Miner Metab. 2006;24(4):300-6
– reference: 9088063 - Semin Surg Oncol. 1997 Mar-Apr;13(2):78-86
– reference: 19103739 - Nephrol Dial Transplant. 2009 Mar;24(3):707-9
– reference: 11044218 - Kidney Int. 2000 Nov;58(5):1980-6
– reference: 16810308 - Kidney Int Suppl. 2006 Jul;(102):S3-7
– reference: 7830860 - Nephron. 1994;68(2):221-8
– reference: 10770968 - J Am Soc Nephrol. 2000 May;11(5):903-11
– reference: 18945995 - Clin J Am Soc Nephrol. 2008 Nov;3(6):1718-25
– reference: 17568787 - Kidney Int. 2008 Aug;74(3):276-88
– reference: 8636374 - J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606
– reference: 15673294 - Kidney Int. 2005 Feb;67(2):467-76
– reference: 14605286 - Nephrol Dial Transplant. 2003 Dec;18(12):2613-21
– reference: 12595492 - J Am Soc Nephrol. 2003 Mar;14(3):575-83
SSID ssj0044325
Score 2.3541467
Snippet Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has not been proven whether...
Background and objectives: Cinacalcet is effective in reducing serum parathyroid hormone (PTH) in patients with secondary hyperparathyroidism. However, it has...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2305
SubjectTerms Aged
Cinacalcet Hydrochloride
Female
Humans
Hyperparathyroidism, Secondary - drug therapy
Hyperparathyroidism, Secondary - metabolism
Hyperparathyroidism, Secondary - pathology
Male
Middle Aged
Naphthalenes - adverse effects
Naphthalenes - therapeutic use
Original
Parathyroid Glands - drug effects
Parathyroid Glands - pathology
Parathyroid Hormone - blood
Parathyroid Hormone - secretion
Title Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism
URI http://cjasn.asnjournals.org/content/5/12/2305.abstract
https://www.ncbi.nlm.nih.gov/pubmed/20798251
https://www.proquest.com/docview/816793740
https://pubmed.ncbi.nlm.nih.gov/PMC2994093
https://www.ncbi.nlm.nih.gov/pmc/articles/2994093
UnpaywallVersion submittedVersion
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1555-905X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0044325
  issn: 1555-9041
  databaseCode: KQ8
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1555-905X
  dateEnd: 20241002
  omitProxy: true
  ssIdentifier: ssj0044325
  issn: 1555-9041
  databaseCode: DIK
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1555-905X
  dateEnd: 20241002
  omitProxy: true
  ssIdentifier: ssj0044325
  issn: 1555-9041
  databaseCode: GX1
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1555-905X
  dateEnd: 20241002
  omitProxy: true
  ssIdentifier: ssj0044325
  issn: 1555-9041
  databaseCode: RPM
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZGJ8ET90sQTEYCXlDaJLaT-nGqGNWkVdVGUXmyHMdhGalTNalQ93P4pRznto2BBG-RcmL7yJ_t79jHXxB6y6IkHce-7wY68VyakNSNfcJcFY6l9rXiKrG3kU9m4XRBj5dsuYf87i5MnbSv4mxo8tXQZOd1buV6pUZdntgI5k-IScgdtB_aM6UB2l_M5odfa11UxlzuUf_qmS2bZPcAVraRujBDzwY8xN6Xvb4MddLAf6KZt7Ml723NWu5-yDy_thQdPUCnnRNNBsr34baKh-ryN33H__LyIbrfElN82Lx6hPa0eYzunrRH70_Qz0lmJHSo0hVuJI9hnsx3-NRqv-oSz62G-PluU2QJngIRLozGZ5aT2p7H0iT4k02ixF_q6RA--wbYhDaUuEjxHMy6jPfW7iy71DgzUG4t_Fpiu2NsSyzs1scOTyGA3qyvKs3K1VO0OPr4eTJ12x88uAp4YOXyOAKYQAglU08pqpJEqpRLICFKW9EanciAyiigMA0FaQRUVmuPShJSpRgJFXmGBgbceYEwpzJmJGXaJxEFTssJI5RrjwfSozFPHfSh62-hWvVz-xOOXEAUZNEhJscz0aHDQe9663Wj-vEXuzcddES5AkAAUgKhLmRpmPADAfEdcxDuMCVg6NrzGGl0sS3F2B6BQXOhmOcNxPrKAi_i9lKxg6Ib4OsNrCr4zTcAo1odvEWOg973ML3lA4yE3oeX_2r4Cg2qzVa_BhJWxQf1vthBO_h-AdREN7g
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZGJ8ET90sQICMBLyhtEttJ_ThVjGrSqmqjqDxZjuNsGalTNalQ93P4pRznto2BBG-RfOLkyJ_t79jHnxF6x6IkHce-7wY68VyakNSNfcJcFY6l9rXiKrGnkY9n4XRBj5ZsuYf87ixMnbSv4mxo8tXQZOd1buV6pUZdntgIxk-IScgdtB_aPaUB2l_M5gffal1UxlzuUf_qmS2bZPcAZraRujBDzwY8xJ6XvT4NddLAf6KZt7Ml723NWu5-yDy_NhUdPkAnnRNNBsr34baKh-ryN33H__LyIbrfElN80BQ9QnvaPEZ3j9ut9yfo5yQzEhpU6Qo3kscwTuY7fGK1X3WJ51ZD_Hy3KbIET4EIF0bjU8tJbctjaRL82SZR4q_1cAivnQE24R9KXKR4DmZdxntrd5pdapwZqLcWfi2xXTG2NRZ26WOHpxBAb9ZXH83K1VO0OPz0ZTJ12wseXAU8sHJ5HAFMIISSqacUVUkiVcolkBClrWiNTmRAZRRQGIaCNAIqq7VHJQmpUoyEijxDAwPuvECYUxkzkjLtk4gCp-WEEcq1xwPp0ZinDvrYtbdQrfq5vYQjFxAFWXSIydFMdOhw0Pveet2ofvzF7m0HHVGuABCAlECoC1kaJvxAQHzHHIQ7TAnounY_RhpdbEsxtltg8LtQzfMGYv3HAi_i9lCxg6Ib4OsNrCr4zRKAUa0O3iLHQR96mN7yAXpC78PLfzV8hQbVZqtfAwmr4jdtt_sFi0I2qA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cinacalcet+Effectively+Reduces+Parathyroid+Hormone+Secretion+and+Gland+Volume+Regardless+of+Pretreatment+Gland+Size+in+Patients+with+Secondary+Hyperparathyroidism&rft.jtitle=Clinical+journal+of+the+American+Society+of+Nephrology&rft.au=Komaba%2C+Hirotaka&rft.au=Nakanishi%2C+Shohei&rft.au=Fujimori%2C+Akira&rft.au=Tanaka%2C+Motoko&rft.date=2010-12-01&rft.issn=1555-9041&rft.volume=5&rft.issue=12&rft.spage=2305&rft.epage=2314&rft_id=info:doi/10.2215%2FCJN.02110310&rft.externalDBID=n%2Fa&rft.externalDocID=10_2215_CJN_02110310
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1555-9041&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1555-9041&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1555-9041&client=summon